சஞ்சய் சுப்ரமணியன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சஞ்சய் சுப்ரமணியன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சஞ்சய் சுப்ரமணியன் Today - Breaking & Trending Today

Ocugen, Inc. (OCGN) Q2 2021 Earnings Call Transcript

OCGN earnings call for the period ending June 30, 2021. ....

United States , Kristen Kluska , Keay Nakae , Kristen Kluska Cantor Fitzgerald , Ken Inchausti , Keay Nakae Chardan , Sanjay Subramanian , Robert Leboyer , Shankar Musunuri , Drug Administration , Rk Swayampakula Hc Wainwright Co , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Cantor Fitzgerald , Public Health Agency Of Canada , Health Canada , Investor Relations , Chief Executive , Public Health Agency , Bharat Biotech , Jubilant Hollisterstier , Financial Officer , Capital Markets , New England Journal , Immunology Journal ,

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial - read this article along with other careers information, tips and advice on BioSpace ....

United States , Sanjay Subramanian , Shankar Musunuri , Sharon Correia , Michael Shine , Villanova University , Drug Administration , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Master Of Business Administration , University Of Scranton , Health Canada , Senior Vice President , Novapharm Therapeutics , Colgate Oral Pharmaceutical , Pfizer Vaccines , Chief Marketing Officer , Thomas Reuters , Chief Executive Officer , Business Administration , Bharat Biotech , Private Securities Litigation Reform Act , Financial Officer , Vice President , Cugen Inc Announces Michael Shine As Senior Vice President ,

Ocugen Inc. Announces Michael Shine as Senior Vice

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and. ....

United States , Sanjay Subramanian , Shankar Musunuri , Michael Shine , Villanova University , Drug Administration , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Master Of Business Administration , University Of Scranton , Health Canada , Senior Vice President , Novapharm Therapeutics , Colgate Oral Pharmaceutical , Pfizer Vaccines , Chief Marketing Officer , Thomas Reuters , Chief Executive Officer , Business Administration , Bharat Biotech , Private Securities Litigation Reform Act , Financial Officer , Nasdaq Ocgn , ஒன்றுபட்டது மாநிலங்களில் , சஞ்சய் சுப்ரமணியன் ,

Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript

Operator
Good morning and welcome to the Ocugen conference call. At this time, all participants are in listen-only mode. [Operator instructions] Please note this conference is being recorded. I would now like to turn the conference over to Lisa DeScenza, vice president of integrated communications at LaVoie Health Science to introduce the Ocugen team.
You may begin.
Vice President of Integrated Communications
Thank you, operator. I d like to welcome you to our conference call. With me today are Ocugen s chairman and CEO, Dr. Shankar Musunuri, and our CFO and head of corporate development, Sanjay Subramanian.
Earlier this morning Ocugen issued a press release, including a business update and first-quarter 2021 financial results. We encourage listeners to review the press release, which is available on the Ocugen website at www.ocugen.com. This call is also being recorded and a replay will be available on the Investor section of the Ocugen website for approximate ....

United States , Sanjay Subramanian , Shankar Musunuri , Keay Nakae , Anthony Fauci , Keay Nakae Chardan , Lisa Descenza , Lavoie Health Science , Biomedical Advanced Research , World Health Organization , Drug Administration , Development Authority , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Association For Research , Private Securities Litigation Reform Act , Bharat Biotech , Risk Factors , Chief Executive , Financial Officer , ஒன்றுபட்டது மாநிலங்களில் , சஞ்சய் சுப்ரமணியன் , லிசா சேசென்ச , லாவோய் ஆரோக்கியம் அறிவியல் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,

Ocugen Provides Business Update and First Quarter 2021 Financial Results

and Variant Neutralization Results In April 2021, Ocugen announced that its co-development partner, Bharat Biotech International Limited ( Bharat Biotech ), shared positive results from the second interim analysis of its Phase 3 clinical trial of COVAXIN showing 78% overall efficacy against COVID-19 disease, 100% efficacy against severe COVID-19 disease (including hospitalization), and 70% efficacy against asymptomatic COVID-19 infection, indicating the potential to significantly reduce virus transmission. COVAXIN has additionally demonstrated a remarkable safety profile with several million doses administered to date in India. Moreover, in-vitro studies conducted by the Indian Council of Medical Research-National Institute of Virology have provided data suggesting effectiveness in neutralizing the double mutant India variant, the U.K. variant, and the Brazil variant. Based on broad immunogenicity, Ocugen believes that COVAXIN has the potential to be effective against other eme ....

United States , Sanjay Subramanian , John Paul Gabriel , Shankar Musunuri , Lisa Descenza , National Institute Of Virology , Biomedical Advanced Research , Head Of Corp , Drug Administration , Indian Council Of Medical Research , Development Authority , Ocugen Inc , Exchange Commission , Bharat Biotech International Limited , Conference Call , Webcast Today , Emergency Use Authorization , Bharat Biotech , Chief Executive Officer , Variant Neutralization Results , Indian Council , Medical Research National Institute , Use Authorization , Master File , Hired Significant Key Talent , Senior Vice President ,